Navigation Links
VolitionRx Files Two Patent Applications
Date:4/4/2013

NAMUR, Belgium, April 4, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has filed two new patent applications. The first patent application is an extension to the Nucleosomics® technology for the detection of histone modifications in nucleosomes; the second covers the use of Volition's Nucleosomics® technology in personalized medicine as a predictor of the efficacy of cancer treatment.

"The use of Nucleosomics in the expanding field of personalized cancer medicine is a new early stage development for us but represents an exciting prospect with the potential for real patient benefit," said Jake Micallef , Chief Scientific Officer of Belgian Volition.

VolitionRx already holds patent applications worldwide for a number of methods of detecting nucleosomes and nucleosome structures; both in-licensed and self-authored.

"These two patents complement our existing Nucleosomics IP, providing us with greater intellectual property protection for our NuQ® products," said Cameron Reynolds , CEO of VolitionRx. "While we work towards applying for regulatory approval for our clinical products in both Europe and the US, we continue to carry out research and development in our Belgian laboratory, expanding our intellectual property base and our understanding of the possibilities – both in diagnostics and therapy monitoring – for our Nucleosomics technology."

About VolitionRx
VolitionRx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.

VolitionRx's development activities are currently centered in Belgium with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.

You can find more information about VolitionRx at our website at www.volitionrx.com, on Twitter at http://www.twitter.com/VolitionRx, LinkedIn at www.linkedin.com/company/1364072?trk=tyah or Facebook at www.facebook.com/volitionrx.

Safe Harbor Statement

Statements in this press release may be "forward-looking statements"Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE VolitionRx Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
2. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
5. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
6. Sunpeaks Ventures Files Defamation Lawsuit
7. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
8. SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
9. DataMotion Files Provisional Patent for Technology that Enables Easy and Secure Doctor-Patient Email Interaction
10. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
11. Acella Pharmaceuticals, LLC, files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration for Topical Corticosteroids Lotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... , ... Journal of Oral Implantology – Tooth loss is not ... health, including complications with speech, eating, and overcompensation of mouth due to the deficiency. ... As the number of tooth replacements increase, it is imperative to design an implant ...
(Date:4/26/2017)... ... 2017 , ... Elisabete Miranda, president and CEO of ... magazine as one of its 2017 Enterprising Women of the Year, a prestigious ... that they have fast-growth businesses, mentor or actively support other women and girls ...
(Date:4/26/2017)... NJ (PRWEB) , ... April 26, 2017 , ... RawTrition ... an easy way to get nutrients from SUPERFOODS! , RawTrition is taking ... at the cellular level because the body recognizes its raw form (unlike the synthetically ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, ... to announce that it has received 510(k) clearance from the U.S. Food & ... the MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition Duchenne, ... Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on ... clinical trial in Duchenne announced today. , Coalition Duchenne funded studies carried ...
Breaking Medicine News(10 mins):